These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25793625)

  • 21. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
    Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
    Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
    Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
    Carvalho TN; Kobs VC; Hille D; Deglmann RC; Melo LH; França PHC
    Rev Soc Bras Med Trop; 2023; 56():. PubMed ID: 36700602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 30. Involvement of the Multidrug Efflux Pumps in Betalactams Resistant Pseudomonas aerugionsa Clinical Isolates Collected from Burn Patients in Iran.
    Bijari A; Azimi L; Fallah F; Ardebili A; Lari ER; Lari AR
    Infect Disord Drug Targets; 2016; 16(3):172-177. PubMed ID: 27572250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection and characterization of cefepime-resistant gram-negative bacteria.
    Piddock LJ; Griggs DJ
    J Antimicrob Chemother; 1991 Nov; 28(5):669-76. PubMed ID: 1778870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria.
    Piddock LJ; Traynor EA
    J Antimicrob Chemother; 1991 Aug; 28(2):209-19. PubMed ID: 1778852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
    Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
    Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae.
    Vera-Leiva A; Carrasco-Anabalón S; Lima CA; Villagra N; Domínguez M; Bello-Toledo H; González-Rocha G
    J Glob Antimicrob Resist; 2018 Mar; 12():73-76. PubMed ID: 29275225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. beta-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of Gram-negative extraintestinal clinical isolates.
    Gál Z; Szabó D; Kovács P; Hernádi F; Tóth-Martinez B; Rozgonyi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):395-400. PubMed ID: 11118847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B; Zamorano L; Juan C; Pérez JL; Ge Y; Oliver A
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance.
    Paladino JA; Sunderlin JL; Singer ME; Adelman MH; Schentag JJ
    Am J Health Syst Pharm; 2008 Jun; 65(12):1154-9. PubMed ID: 18541686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.